Genetic Signatures Limited
(ASX:GSS) has announced a new appointment to the Board of Directors.
Dr Tony Radford has joined the board of the specialist molecular diagnostics company.
Chairman Dr Nick Samaras PhD says Dr Radford’s experience as one of Australia’s most distinguished senior biotech executives will add considerable value to Genetic Signatures.
Dr Radford was previously CEO of Cellestis from founding until its acquisition in 2011 for approximately $400 million.
Genetic Signatures recently expanded into Ireland and Poland, signing distribution deals for its infectious disease detection products.
Genetic Signatures reported a net loss of $2.65 million for FY15.
